PURPOSE: To analyze long-term prognosis and morbidity after limb-sparing treatment of patients with extremity soft-tissue sarcoma, with intraoperative electron boost radiotherapy (IOERT) followed by a moderate dose of external beam radiotherapy (EBRT). METHODS AND MATERIALS: A total of 153 patients who were treated in a single center from 1991 to 2004 were evaluated. Median IOERT dose was 15 Gy, mean EBRT dose 43 Gy (range, 40-50.4 Gy) in conventional fractionation (1.8-2 Gy). Median duration of follow-up was 33 months. Acute toxicity was assessed with Common Toxicity Criteria; late toxic effects were scored according to European Organization for Research and Treatment of Cancer/Radiation Therapy Oncology Group criteria. RESULTS: Five-year overall survival and 5-year local control rates were 77% and 78%, respectively. Whereas tumor size, patient age, and EBRT dose did not significantly affect outcome, resection status and grading were significant for survival; resection status and IOERT dose were significant for local control. Extremity salvage until death or time of follow-up was achieved in 90% of our patients, 86% of whom showed excellent limb function without impairment in activities of daily life. Acute toxicity Grade 2-4 was observed in 23% and late toxicity Grade 2-4 in 17% of patients. CONCLUSIONS: Treatment with IOERT combined with moderate doses of external beam irradiation yields high local control and extremity preservation rates in resected extremity soft-tissue sarcoma.
PURPOSE: To analyze long-term prognosis and morbidity after limb-sparing treatment of patients with extremity soft-tissue sarcoma, with intraoperative electron boost radiotherapy (IOERT) followed by a moderate dose of external beam radiotherapy (EBRT). METHODS AND MATERIALS: A total of 153 patients who were treated in a single center from 1991 to 2004 were evaluated. Median IOERT dose was 15 Gy, mean EBRT dose 43 Gy (range, 40-50.4 Gy) in conventional fractionation (1.8-2 Gy). Median duration of follow-up was 33 months. Acute toxicity was assessed with Common Toxicity Criteria; late toxic effects were scored according to European Organization for Research and Treatment of Cancer/Radiation Therapy Oncology Group criteria. RESULTS: Five-year overall survival and 5-year local control rates were 77% and 78%, respectively. Whereas tumor size, patient age, and EBRT dose did not significantly affect outcome, resection status and grading were significant for survival; resection status and IOERT dose were significant for local control. Extremity salvage until death or time of follow-up was achieved in 90% of our patients, 86% of whom showed excellent limb function without impairment in activities of daily life. Acute toxicity Grade 2-4 was observed in 23% and late toxicity Grade 2-4 in 17% of patients. CONCLUSIONS: Treatment with IOERT combined with moderate doses of external beam irradiation yields high local control and extremity preservation rates in resected extremity soft-tissue sarcoma.
Authors: Esther Carbó-Laso; Pablo Sanz-Ruiz; José Antonio Calvo-Haro; Miguel Cuervo-Dehesa; Rubén Pérez-Mañanes; Lydia Mediavilla-Santos; Coral Sánchez-Pérez; Ana Álvarez-González; Javier Vaquero-Martín Journal: Int J Clin Oncol Date: 2017-07-17 Impact factor: 3.402
Authors: M Krengli; F A Calvo; F Sedlmayer; C V Sole; G Fastner; M Alessandro; S Maluta; R Corvò; E Sperk; M Litoborski; C Pisani; C Fillini; F Fusconi; M F Osti; L Tomio; H Marsiglia; A Ciabattoni; W Polkowski; A Di Grazia; A Gava; A Kuten; C Iotti; C Gonzalez; M Sallabanda; J-B Dubois; G Catalano; V Valentini Journal: Strahlenther Onkol Date: 2013-07-12 Impact factor: 3.621
Authors: Felipe A Calvo; Claudio V Sole; Alfredo Polo; Mauricio Cambeiro; Angel Montero; Ana Alvarez; Miguel Cuervo; Mikel San Julian; Rafael Martinez-Monge Journal: Strahlenther Onkol Date: 2014-04-09 Impact factor: 3.621
Authors: Christopher L Tinkle; Vivian Weinberg; Steve E Braunstein; Rosanna Wustrack; Andrew Horvai; Thierry Jahan; Richard J O'Donnell; Alexander R Gottschalk Journal: Sarcoma Date: 2015-08-09
Authors: Falk Roeder; Burkhard Lehner; Thomas Schmitt; Bernd Kasper; Gerlinde Egerer; Oliver Sedlaczek; Carsten Grüllich; Gunhild Mechtersheimer; Patrick Wuchter; Frank W Hensley; Peter E Huber; Juergen Debus; Marc Bischof Journal: BMC Cancer Date: 2014-05-20 Impact factor: 4.430